



TO STUDY THE EXPRESSION OF PROLIFERATING CELL NUCLEAR ANTIGEN (PCNA) IN LEUKOPLAKIA WITH AND WITHOUT DYSPLASIA AND NORMAL ORAL MUCOSA.

Dr Vikas Sharma¹, Tanushree Sharma², Dr Aseem Sharma^{3*}, Dr. Isha sharma⁴

¹Reader, Department Of Oral Pathology And Microbiology, Dest Bhagat Dental College, Mandi Govindgarh, Punjab.

²Senior Resident At The Department Of Dentistry GMC Kathua Jandk.

^{3*}Reader In The Department Of Orthodontics And Dentofacial Orthopedics At HIDS Paonta Sahib HP.

⁴BDS MDS (Oral Pathologist) Ex-Servicemen Contributory Scheme Batala

***Corresponding Author:** Dr. Aseem Sharma

*Reader In The Department Of Orthodontics And Dentofacial Orthopedics At HIDS Paonta Sahib HP.

DOI: 10.48047/ecb/2023.12.si5a.0483

Introduction

Cell proliferation is a biological process that is essential to all living organisms due to its role in the growth and maintenance of the tissue homeostasis¹. The control of this important process is completely deregulated in some types of neoplasia, and the assessment of cell proliferation activity in tumors has become a common tool used by histopathologists to provide useful information for assessing diagnosis, clinical behavior, and therapy. The cell cycle consists of a series of phases, during which there are changes that lead to cell division^{1,2}. Proliferation markers refers to specific proteins or other factors whose presence in actively growing and dividing cells serves as an indicator for such cells. Today, the most common method for determining proliferative activity is the use of immunohistochemical techniques, which are increasingly being applied in routine pathology¹. Biomarkers are now used to characterize different aspects of development of premalignant and malignant lesions and conditions³. Tumorigenesis in head and neck squamous cell carcinoma is proposed to be a multistep process; dysregulation of proliferation is a potential marker of this process⁴. Changes in the proliferative capacity of premalignant oral lesions may provide insight into early preneoplastic changes and yield information about the risk of malignant transformation. The results till date have suggested that disordered proliferation may be an early consequence of carcinogen exposure and simultaneous field cancerization².

Proliferating Cell Nuclear Antigen (PCNA) expression pattern can be helpful in the comprehension of the process of tumorigenesis, since there is a gradual increase in terms of the number of PCNA-positive cells with the progress from normal epithelium to malignancy

Material and Methods

This study was undertaken in order to detect the presence of Proliferating Cell Nuclear Antigen (PCNA) in Normal oral mucosa, oral submucous fibrosis, and oral leukoplakia with or without dysplasia under light microscope. These samples were taken from the archive of the department of oral pathology and microbiology, D.J College of dental sciences and research, Modinagar. The study comprised of control group and study group. Samples were divided into four different groups: Group I was a control group (NOM); Group II was further divided into 3 subgroups: Group IIA includes 15 patients with oral submucous fibrosis; Group IIB included 15 patients with oral

leukoplakia without dysplasia; Group IIC included 15 patients with oral leukoplakia with dysplasia. Group I (Control group) included only non-smokers with no history of areca/betel quid chewing. Out of the 10 control subjects, 8 were men and 2 were women and their age range was from 18 to 30 years. In group IIA, the male: female ratio was 9:1 and age ranges was from 20 to 62 years. These cases were diagnosed histopathologically as moderate to severe grades of OSMF. In group IIB and IIC, all patients were men and their age ranges from 25 to 68 years.

The diagnosis for each oral lesion was combined with histological examination of hematoxylin and eosin stained sections..

Immunohistochemistry

The demonstration of antigens by immunohistochemistry is a two-step process involving first, the binding of a primary antibody to the antigen of interest, and second, the detection of bound antibody by a chromogen.

Reagent used for IHC staining

Super Sensitive Polymer-HRP IHC Detection System kit was used. Contents: Hydrogen peroxidase (6 ml vial, 3% H₂O₂ in water); Power Block™ Reagent HK083-5K: One vial (6 ml) of a highly effective universal protein blocking reagent. (Contains casein and proprietary additives in PBS with 0.09% sodium azide); Secondary antibody (Biotinylated anti-rabbit, antimouse and anti-goat immunoglobulin in phosphate buffered saline containing carrier protein on 15mM azide); Streptavidin peroxidase (Streptavidin conjugated horse radish peroxidase in phosphate buffered saline containing carrier protein and antimicrobial agent); Buffered substrate (Buffered substrate solution, pH 7.2, containing hydrogen peroxide and a preservative); DAB chromogen (3,3- diamino benzidine chromogen solution) [25]. Anti PCNA (prediluted, BIOGENEX Corporation, CA, USA); Phosphate buffered saline (PBS); Xylene; Absolute alcohol; 95% alcohol; Distilled water; Mayers Haematoxylin; 1% acid alcohol; Mounting medium (DPX). The following reagents were prepared prior to staining. Phosphate buffered saline (PBS) (Wash solution, buffer bath) 0.05 M/L, 0.1mol /L NaCl (pH 7.2-7.6). Citrate buffer: 10m mol/L citrate (pH 6.0). Substrate chromogen solution (4-7 sections): Transfer 1ml aliquot of buffered substrate into the calibrated test tube. To this add one drop (approximately 20 µl) of DAB chromogen.



PHOTOGRAPH. SUPER SENSITIVE POLYMER HRP- IHC DETECTION KIT

Procedure:

Formalin fixed paraffin embedded tissues were sectioned at 3 μ m and mounted on silane-coated slides. The slides were incubated in a pre-heated incubator at 37 $^{\circ}$ C for overnight. Slides were treated with two changes of Xylene for 5 minutes each for deparaffinization and hydrated by treating with one change each of 100% alcohol followed by graded alcohol 90%, 70%, 50%, for 5min each. The slides were rinsed with the running tap water. Antigen retrieval was done using heat induced epitopes retrieval (HIER) microwave oven method. The slides were kept in a coupling jar filled with PBS buffer (pH 6) and placed in a microwave oven. Slides were given two cycle at high (80 $^{\circ}$ C) mode of microwave for 15 minutes, one cycle at medium high (60 $^{\circ}$ C) for 5 minutes and one cycle at low (40 $^{\circ}$ C) mode for 5 minutes. After every cycle buffer was added to fill the coupling jar. The sections were then allowed to cool to room temperature and then rinsed with distill water for 1 minutes and then washed with PBS buffer thrice for 5 minutes each. All the incubations were carried out at room temperature, with a humidifying chamber. At no time, the tissue sections were permitted to dry during the staining procedure: Step 1: Blocking endogenous peroxidases: Endogenous peroxidase activity was blocked by incubating the slides with peroxide block (3% hydrogen peroxide in water) for 12-15 minutes. Sections were again washed with wash buffer thrice for 5 minutes. Step 2: Sections were treated with Power Block (A highly effective universal protein blocking reagent. Contains casein and proprietary additives in PBS with 15m sodium azide) for 12-15 minutes. No washing was done after the incubation in Power Block. Step 3: Application of primary antibody: Sections were incubated with mouse anti-rat monoclonal PCNA (Bio Genex) for 1 hour in a humidifying chamber at 37 $^{\circ}$ C. Sections were then washed thrice with wash buffer for 3 minutes each. Step 4: The sections were incubated with Super Enhancer (A reagent that enhances the signal and is

used after the primary antibody incubation) for 25 minutes and were again washed thrice with wash buffer for 5 minutes each. Step 5: Secondary antibody application: Slides were then incubated with Super sensitive poly HRP (anti-mouse anti-rabbit IgG labeled with enzyme polymer in phosphate buffered saline with stabilizers, carrier protein and 0.1% Proclin 300) secondary antibody for 30 minutes in a humidifying chamber and were washed thrice with wash buffer for 5 minutes each. Step 6: Slides were then incubated with 3,3' - diaminobenzidine tetrahydrochloride (DAB) chromogen for 1-5 minutes. Chromogens was freshly prepared by adding 1 ml stable DAB with 1 drop chromogen and 5 microliter of 30% H₂O₂. Step 7: Slides were rinsed with distilled water and counterstained with Harris hematoxylin for 20 seconds followed by bluing in tap water for 10 minutes. The Slides were then dehydrated through graded alcohol, cleared in xylene, and mounted with DPX.

Assessment of PCNA expression: The nuclear expression of PCNA was assessed at 10x and then 40x magnification and manual counting was done using manual counter. Presence of brown colored end product at the site of target antigen was indicative of positive reactivity. The negative control tissue demonstrated absence of specific staining. For qualitative assessment the expression of PCNA was observed in basal, suprabasal and spinous layers on NOM and epithelial dysplasia. The basal layer- nuclei positive in a single layer just above the basement membrane; The suprabasal layer- nuclei positive 2 - 3 layers above the basal layer. The spinous layer- nuclei positive in the superficial layer above the suprabasal layer. Total number of positive cells in each layer i.e. basal, suprabasal and spinous was visually counted using light microscope in epithelial dysplasia and NOM. The percentage of positively stained nuclei for PCNA was counted in three non -overlapping X400 fields by three different observers and then average of the three was calculated.

Statistical analysis:

Data obtained in the present study was subjected to the statistical analysis using SPSS 18 software for one-way ANOVA and independent t-test. One way analysis (ANOVA) test is used to compare the mean scores between more than two groups. Descriptive statistical analysis has been carried out in the present study. Results on continuous measurements are presented on Mean \pm SD (Min Max) and results on categorical measurements are

presented in Number (%). Significance is assessed at 5 % level of significance.

Results:

All specimens showed positive staining for PCNA. Staining was observed in oral epithelium and in

infiltrating inflammatory cells. Staining for PCNA was localized to the nucleus and exhibited a differential pattern of expression in different grades of dysplasia.




Figure: A. leukoplakia with dysplasia (IHC X10) B. Leukoplakia without dysplasia (IHC X10) C. Oral submucous fibrosis (IHC X10), D. Leukoplakia with dysplasia (IHC X40), E. leukoplakia without dysplasia (IHC X40), F.oral submucous fibrosis (IHC X40)

DISCUSSION

It is well understood that the transition of the normal oral epithelium to dysplasia to malignancy is featured by increased cell proliferation. Discovery of various proliferation markers has enabled the detection of the hyperactive state of the epithelium and has been suggested to be of prognostic significance. The basal layer is the only proliferative compartment for normal oral epithelium, whereas in the rest of the epithelial layers, cellular maturation takes place without any proliferative activity. Hence, any sign of proliferative cellular activity beyond the basal layer should be considered as a warning sign¹⁰.

The term “proliferation markers” refers to specific proteins or other factors whose presence in actively growing and dividing cells serve as an indicator for such cells, for example, PCNA and Ki-67¹¹. It has been reported that the proliferating cell growth fractions in oral potentially malignant disorders were significantly higher than those in normal mucosa and suggested that these growth fractions correlated with the degree of severity of dysplasia which linked to the increasing probability in the

development of malignancy¹². This study and other recent studies have shown that nuclear staining for PCNA in dysplastic oral epithelium involved the basal, parabasal and spinous cell layer as compared to normal and hyperplastic epithelium where the nuclear PCNA staining was only in the basal area.

Our study shows that the expression of PCNA in group I i.e. leukoplakia with dysplasia was maximum in basal layer followed by suprabasal and least in the spinous layer in all the four groups including normal oral mucosa. The percentage of PCNA positive cells increases with increasing grades of epithelial dysplasia. The results of the present study showed that PCNA expression was seen in all cases of normal oral mucosa, oral submucous fibrosis and leukoplakia with and without dysplasia. The overall percentage of PCNA positive cells increases gradually from normal oral mucosa, through leukoplakia without dysplasia to leukoplakia with dysplasia with significantly higher expression in severe dysplasia. These results are in accordance with previous studies which have shown an increased expression of PCNA as the tissue progresses from normal state to severe

dysplastic stage^{13,14}. These results confirm that an increase cell proliferation is a characteristic feature of malignancy. Higher the cell proliferation rate the higher is the risk of cells suffering mutations and effect of carcinogens during mitosis which could result in malignant phenotype¹⁵.

Another important finding obtained by PCNA immunohistochemistry used in the present study is the loss of polarity of PCNA positive cells, particularly in dysplasia and cancer lesions. In normal squamous epithelium, PCNA-positive cells were well localized in the basal layer, but the normal was more or less distributed in hyperplasia and mild dysplasia and remarkably distributed in higher grades of dysplasia. These findings indicates the presence of disturbed cell differentiation and proliferation in the dysplastic epithelium which in later stages may undergoes malignant transformation.

Hence based on the findings of the present study it can be concluded that PCNA can be used as a useful marker in objectively grading oral epithelial dysplasia in certain lesions such as leukoplakia.

Conclusion

Hence we can say that PCNA can be used as a diagnostic as well as a prognostic markers for premalignant and malignant lesions. By using PCNA as a diagnostic marker in premalignant lesions, one can avoid many subjective errors. PCNA can play an important role in objectively grading dysplasia in certain oral premalignant disorders such as leukoplakia. Further studies with a higher sample size will be essential to prove the suitability of PCNA in the different layers of the epithelium as a marker for determining the degree of dysplasia.

Conflict of Interest: The authors declare that there was no conflict of interest.

REFERENCES

1. Bologna-Molina R, Mosqueda-Taylor A, Molina-Frechero N, Mori-Estevez AD, Sánchez-Acuña G. Comparison of the value of PCNA and Ki-67as markers of cell proliferation in ameloblastic tumors. *Med Oral Patol Oral Cir Bucal*. 2013; 18 (2): 174-9.
2. Kaur M, Saxena S, Bansal P. Expression of Proliferating Cell Nuclear Antigen in Normal Oral Mucosa, Oral Submucous Fibrosis and Leukoplakia With Or Without Dysplasia. *Int J Oral-Med Sci*. 2011; 10(3):149-155.
3. Lawall MA, Crivelini. PCNA and p53 expression in oral leukoplakia with different degrees of keratinization. *J Appl Oral Sci*. 2011; 14(4): 276-80.
4. Shin DM, Voravud N, Ro JY, Lee JS, Hong WK, Hittelman WN. Sequential increases in proliferating cell nuclear antigen expression in head and neck tumorigenesis: a potential biomarker. *J Natl Cancer Inst*. 1993;85(12): 971-8.
5. Shin DM, Kim J, Ro JY, Hittelman J, Roth JA, Hong WK, Hittelman WN. Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis. *Cancer Res*. 1994;54(2): 321-6.
6. Huang WY, Coltrera M, Schubert M, Morton T, Truelove E. Histopathologic evaluation of proliferating cell nuclear antigen (PC10) in oral epithelial hyperplasias and premalignant lesions. *Oral Surg Oral Med Oral Pathol*. 1994; 78(6): 748-54.
7. Tsuji T, Mimura Y, Wen S, Li X, Kanekawa A, Sasaki K, et al. The significance of PCNA and p53 protein in some oral tumors. *Int J Oral Maxillofac Surg*. 1995; 24(3): 221-5.
8. Iwasa.M, Imamura.Y, Noriki. S, Nishi. Y, Kato. H, and Fukuda. M. Immunohistochemical detection of early-stage carcinogenesis of oral leukoplakia by increased DNA-instability and various malignancy markers. *Eur. J. Histochem*. 2001; 45(4): 333-346
9. Nishioka H, Hiasa Y., Hayashi I., Kitahori Y., Konishi N., and Sugimura M.: Immunohistochemical detection of p53 Oncoprotein in human oral squamous cell carcinomas and leukoplakias: comparison with proliferating cell nuclear antigen staining and correlation with clinicopathological findings. *Oncology*. 1993; 50(6): 426-429.
10. Dwivedi N, Chandra S, Kashyap B, Raj v, Agarwal A. Suprabasal expression of Ki- 67 as a marker for severity of oral epithelial dysplasia and oral squamous cell carcinoma. *Contemporary Clinical Dentistry*. 2013; 4(1): 7-12
11. Azzawi LM, Layla S. Immunohistochemical expression of p53 and PCNA proteins in oral lichen planus and oral dysplasia. *J BaghColl Dentistry*. 2014; 26(1):98-102.
12. Strzalka W and Ziemienowicz A. Proliferating cell nuclear antigen (PCNA): a key factor in DNA replication and cell cycle regulation. *Annals of Botany*. 2011; 107: 1127–1140
13. Steinbeck RG, Moege J, Heselmeyer KM, Klebe W, Neugebauer W, Borg B, Auer GU. DNA content and PCNA immunoreactivity in

- oral precancerous and cancerous lesions. *Eur J Cancer B Oral Oncol.* 1993; 29(4):279-84.
14. Mittal KR, Demopoulos R, Goswami S. Proliferating cell nuclear antigen (cyclin) expression in normal and abnormal cervical squamous epithelia. *Am J Surg Pathol.* 1993 Feb; 17(2):117-22.
 15. Srinivasan M, Jewell SD. Evaluation of TGF-alpha and EGFR expression in oral leukoplakia and oral submucous fibrosis by quantitative immunohistochemistry. *Oncology.* 2001; 61: 284-92.
 16. Zain RB, Sakamoto F, Shrestha P, Mori M. Proliferating cell nuclear antigen (PCNA) expression in oral squamous cell carcinoma - an aid to conventional histological grading?. *Malaysian J Path.* 1995; 17(1): 23 - 30
 17. Lan HA, Zain RB, Saitoh, M, Muramatsu, Y, Shrestha P, Mori M. *Anticancer Research.* 1996; 16: 5-8.